Does Ozempic actually work? What the response rate data shows

What's this video probably claiming?

Based on the caption, @virgojayv appears to be pushing back against people who credit Ozempic for her weight loss or body changes, insisting the drug did nothing for her. This is a layered claim. She may be saying she lost weight through her own effort, that the drug was ineffective for her specifically, or that others are dismissing her hard work by attributing her results to the medication. With 110K views, this framing lands in a crowded space of "I did it myself" narratives that often undermine accurate public understanding of how GLP-1 receptor agonists actually work. It is worth separating the personal experience angle from the clinical reality, because both things can be true: some individuals do have blunted responses to semaglutide, and at the same time, the drug's efficacy in populations is well-documented.

What does the science actually show?

Semaglutide at 2.4 mg weekly produced mean weight loss of 14.9% of body weight over 68 weeks in the STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine), compared to 2.4% with placebo. That is not subtle. But averages hide variance. In STEP 1, roughly 31% of participants on semaglutide lost less than 5% of body weight, meaning a meaningful minority saw limited results. A 2022 analysis in Obesity (Kushner et al.) found that non-response was associated with factors including baseline metabolic rate, gut microbiome composition, adherence, and how quickly dose escalation occurred. So yes, some people genuinely do not respond strongly to semaglutide. The claim that the drug "did absolutely nothing" is plausible for a subset of users, but it is not representative of typical outcomes, and presenting one person's experience as a general truth misleads the larger audience.

Where does the social media noise diverge from clinical reality?

TikTok has a structural problem with GLP-1 content: the loudest voices are often people at the extremes, either dramatic transformations or frustrated non-responders. The algorithmic incentive rewards both. What gets lost is the clinical nuance. Semaglutide works primarily by activating GLP-1 receptors in the hypothalamus to reduce appetite and slow gastric emptying. If someone had already significantly reduced caloric intake through behavioral change before starting the drug, the appetite-suppression effect may appear invisible because the behavior was already doing that work. This creates a real attribution problem: the drug and the behavior become entangled, and crediting one over the other is genuinely difficult without controlled conditions. Social media treats this as a morality debate about effort and cheating rather than a pharmacokinetic question. That framing is counterproductive for anyone trying to make an informed decision about treatment.

What should you actually know?

Non-response to semaglutide is real and documented, but it is not the norm. The STEP trials consistently showed clinically meaningful weight loss in the majority of participants across different doses and populations. If someone feels the drug is not working, there are legitimate clinical questions to ask: Was dose escalation completed? Was the medication taken consistently? Are there drug interactions? Is the diagnosis itself accurate? A 2023 paper in Diabetes Care (Davies et al.) noted that response rates improve significantly when behavioral support is integrated with pharmacotherapy. The "Ozempic did nothing" narrative, repeated at scale, may discourage people with obesity-related metabolic conditions from pursuing a treatment that has strong clinical evidence behind it. Individual experience matters, but it does not override population-level trial data, and conflating the two is where this kind of content does real harm.